{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:44:22Z","timestamp":1789404262704,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015518","name":"National Obesity Forum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["20244"],"award-info":[{"award-number":["20244"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jconrel.2024.08.049","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T06:15:46Z","timestamp":1725516946000},"page":"74-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates"],"prefix":"10.1016","volume":"375","author":[{"given":"T.","family":"Tedeschini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Campara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grigoletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Zanotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gabbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Armirotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pasut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.08.049_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108235","article-title":"Antibody drug conjugates: the dos and don\u2019ts in clinical development","volume":"240","author":"Tolcher","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.jconrel.2024.08.049_bb0010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"20","key":"10.1016\/j.jconrel.2024.08.049_bb0015","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-11-1417","article-title":"Antibody conjugate therapeutics: challenges and potential","volume":"17","author":"Teicher","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jconrel.2024.08.049_bb0020","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-021-00484-2","article-title":"The clinical development of antibody\u2013drug conjugates \u2014 lessons from leukaemia","volume":"18","author":"Jabbour","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2024.08.049_bb0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.049_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"MAbs"},{"issue":"8","key":"10.1016\/j.jconrel.2024.08.049_bb0035","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/17425247.2010.501792","article-title":"Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting","volume":"7","author":"Zaki","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.049_bb0040","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1951427","article-title":"Targeting cancer with antibody-drug conjugates: promises and challenges","volume":"13","author":"Dean","year":"2021","journal-title":"MAbs"},{"issue":"12","key":"10.1016\/j.jconrel.2024.08.049_bb0045","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","article-title":"Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin","volume":"15","author":"Austin","year":"2004","journal-title":"Mol. Biol. Cell"},{"issue":"16","key":"10.1016\/j.jconrel.2024.08.049_bb0050","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2024.08.049_bb0055","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.jconrel.2024.08.049_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"15","key":"10.1016\/j.jconrel.2024.08.049_bb0065","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody\u2013drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chemie Int. Ed."},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.049_bb0070","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2024.08.049_bb0075","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab emtansine (T-DM1): an antibody \u2212 drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.jconrel.2024.08.049_bb0080","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-11-0727","article-title":"The effect of different linkers on target cell catabolism and pharmacokinetics\/pharmacodynamics of trastuzumab maytansinoid conjugates","volume":"11","author":"Erickson","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.049_bb0085","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/bc900315y","article-title":"Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates","volume":"21","author":"Erickson","year":"2010","journal-title":"Bioconjug. Chem."},{"issue":"July","key":"10.1016\/j.jconrel.2024.08.049_bb0090","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2021.07.041","article-title":"Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates","volume":"337","author":"Tedeschini","year":"2021","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2024.08.049_bb0095","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/ph14030247","article-title":"Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform","volume":"14","author":"Conilh","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"14","key":"10.1016\/j.jconrel.2024.08.049_bb0100","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1039\/C9SC00285E","article-title":"Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates","volume":"10","author":"Viricel","year":"2019","journal-title":"Chem. Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2024.08.049_bb0105","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","article-title":"Impact of payload hydrophobicity on the stability of antibody\u2013drug conjugates","volume":"15","author":"Buecheler","year":"2018","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.049_bb0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/1535-7163.MCT-16-0343","article-title":"Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody\u2013drug conjugates","volume":"16","author":"Burke","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2024.08.049_bb0115","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"17","key":"10.1016\/j.jconrel.2024.08.049_bb0120","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1021\/acs.biochem.2c00358","article-title":"Cathepsin B dipeptidyl carboxypeptidase and endopeptidase activities demonstrated across a broad PH range","volume":"61","author":"Yoon","year":"2022","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.jconrel.2024.08.049_bb0125","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"issue":"10","key":"10.1016\/j.jconrel.2024.08.049_bb0130","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1124\/dmd.114.058511","article-title":"Differential effect of liver cirrhosis on the pregnane X receptor\u2013mediated induction of CYP3A1 and 3A2 in the rat","volume":"42","author":"De Martin","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.jconrel.2024.08.049_bb0135","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrc1949","article-title":"Cysteine cathepsins: multifunctional enzymes in cancer","volume":"6","author":"Mohamed","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"23","key":"10.1016\/j.jconrel.2024.08.049_bb0140","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/S0960-894X(98)00609-X","article-title":"Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin","volume":"8","author":"Dubowchik","year":"1998","journal-title":"Bioorganic Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.jconrel.2024.08.049_bb0145","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-labile Dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.jconrel.2024.08.049_bb0150","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1021\/acs.bioconjchem.1c00124","article-title":"Enzyme-agnostic lysosomal screen identifies new legumain-cleavable ADC linkers","volume":"32","author":"Miller","year":"2021","journal-title":"Bioconjug. Chem."},{"issue":"24","key":"10.1016\/j.jconrel.2024.08.049_bb0155","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-17-2391","article-title":"Cathepsin B is dispensable for cellular processing of cathepsin B-cleavable antibody\u2013drug conjugates","volume":"77","author":"Caculitan","year":"2017","journal-title":"Cancer Res."},{"issue":"41","key":"10.1016\/j.jconrel.2024.08.049_bb0160","doi-asserted-by":"crossref","first-page":"13613","DOI":"10.1039\/D1SC02973H","article-title":"Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody\u2013drug conjugates","volume":"12","author":"Kang","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2024.08.049_bb0165","series-title":"Antibody-Drug Conjugates Methods and Protocols","volume":"vol. 2078","author":"Tumey","year":"2020"},{"issue":"5","key":"10.1016\/j.jconrel.2024.08.049_bb0170","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1535-7163.MCT-15-1004","article-title":"Molecular basis of valine-Citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design","volume":"15","author":"Dorywalska","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.jconrel.2024.08.049_bb0175","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1021\/acs.bioconjchem.6b00316","article-title":"Structural characterization of cross-linked species in trastuzumab emtansine (Kadcyla)","volume":"27","author":"Chen","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2024.08.049_bb0180","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1007\/s11095-014-1584-z","article-title":"Preclinical pharmacokinetic considerations for the development of antibody drug conjugates","volume":"32","author":"Kamath","year":"2015","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2024.08.049_bb0185","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1021\/bc200212a","article-title":"Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody\u2013drug conjugates in rats","volume":"22","author":"Boswell","year":"2011","journal-title":"Bioconjug. Chem."},{"issue":"16","key":"10.1016\/j.jconrel.2024.08.049_bb0190","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1158\/0008-5472.CAN-15-0129","article-title":"A polymer-based antibody-vinca drug conjugate platform: characterization and preclinical efficacy","volume":"75","author":"Yurkovetskiy","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.08.049_bb0195","series-title":"Cancer Drug Discovery and Development","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-3-319-78154-9_9","article-title":"Delivering more payload (high DAR ADCs)","author":"Bodyak","year":"2018"},{"issue":"5","key":"10.1016\/j.jconrel.2024.08.049_bb0200","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1535-7163.MCT-15-1004","article-title":"Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design","volume":"15","author":"Dorywalska","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2024.08.049_bb0205","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","article-title":"Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry","volume":"17","author":"McCombs","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2024.08.049_bb0210","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1021\/acs.molpharmaceut.9b00696","article-title":"Optimizing lysosomal activation of antibody-drug conjugates (ADCs) by incorporation of novel cleavable dipeptide linkers","author":"Salomon","year":"2019","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2024.08.049_bb0215","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1021\/acs.bioconjchem.7b00304","article-title":"Protease-cleavable linkers modulate the anticancer activity of noninternalizing antibody\u2013drug conjugates","volume":"28","author":"Dal Corso","year":"2017","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2024.08.049_bb0220","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bmcl.2005.09.081","article-title":"Dipeptide-based highly potent doxorubicin antibody conjugates","volume":"16","author":"Jeffrey","year":"2006","journal-title":"Bioorganic Med. Chem. Lett."},{"issue":"36","key":"10.1016\/j.jconrel.2024.08.049_bb0225","doi-asserted-by":"crossref","first-page":"8461","DOI":"10.1039\/C9SC00997C","article-title":"Fluorescent probes towards selective cathepsin b detection and visualization in cancer cells and patient samples","volume":"10","author":"Poreba","year":"2019","journal-title":"Chem. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2024.08.049_bb0230","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.jmedchem.7b01430","article-title":"Discovery of peptidomimetic antibody\u2013drug conjugate linkers with enhanced protease specificity","volume":"61","author":"Wei","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.08.049_bb0235","doi-asserted-by":"crossref","DOI":"10.1039\/D3MD00336A","article-title":"ValCitGlyPro-dexamethasone antibody conjugates selectively suppress the activation of human monocytes","author":"Howe","year":"2023","journal-title":"RSC Med. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2024.08.049_bb0240","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4155\/bio.12.299","article-title":"Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics","volume":"5","author":"Kaur","year":"2013","journal-title":"Bioanalysis"},{"issue":"6","key":"10.1016\/j.jconrel.2024.08.049_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2022-004841","article-title":"Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma","volume":"10","author":"Ramamoorthi","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2024.08.049_bb0250","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2017.07.009","article-title":"Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2\/Neu expression","volume":"147","author":"Menderes","year":"2017","journal-title":"Gynecol. Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:20:21Z","timestamp":1762269621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924005996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":50,"alternative-id":["S0168365924005996"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.049","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}